Key Takeaways
- Flattish quarter, deliberate reset: Revenue was "at best flattish" and below management's own expectations, as a deliberate recalibration of field operations and SKU rationalization created near-term disruption.
- Transition now largely complete: The operational changes, including strategic repositioning of brand teams and optimization of field posts, led to elevated attrition but management says team stability and operational momentum have clearly improved.
- Double-digit growth promised from Q4: Management is confident of growth acceleration to double digits from the current quarter itself, aiming for 50% more than industry growth in the short term.
- Yash Pharma acquisition delivering: The acquired business is among the fastest-growing in the portfolio, with margins now aligned to corporate levels and cash flow generation fully aligned.
- What to watch next quarter: Whether the promised double-digit growth materializes in Q4, the pace of field productivity improvement, and any M&A or capital return decision given disciplined intent but high asset prices.
Quarterly Performance & the Internal Reset
- Revenue outcome: Q3 was "at best flattish" with minus 1% growth described as "miniscule degrowth," corroborated by post-GST adjustment and internal improvement initiatives.
- RPM headwind: The market the company is present in grew at less than half the IPM growth, compounding the internal drag.
- Two-quarter soft patch: The first quarter was impacted by GST-related inventory correction; the current quarter was impacted by internal factors including critical actions initiated by the new COO with long-term intent.
- Field operations recalibration: A deliberate overhaul was undertaken to enhance execution excellence, including strategic repositioning of brand teams, optimization of field post-deployment, and resource reallocation of product, brand priority and people priority.
- SKU rationalization: Very small SKUs that were blocking cash versus sales were rationalized; batch size versus sales comparison showed cash blocked on books rather than being sold, and focus is now on larger brands.
- Attrition disruption: The changes led to a phase of elevated attrition, but the transition is now largely complete with clear signs of improved team stability.
- Nine-month resilience: On a nine-month basis, the company delivered resilient performance with 6% top line growth driving 13% bottom line improvement.
- Labour code impact: A one-time cumulative impact of INR 2.1 crores was taken for gratuity and leave encashment relating to past years of service under the new labour code effective from 21st November, though state rules notifications are yet to happen.
Manish Gupta: "The last quarter saw strengthening of our leadership team... Coming to the performance during the quarter, it was at best flattish. We acknowledge that this outcome has been below our own expectations as well as relative to the broader Indian pharmaceutical market."
Leadership & Strategic Direction
- New leadership in place: Amrut Medhekar was appointed as COO and Nirav Vora as CFO in the last quarter; both have settled well and the strategy refresh was undertaken under the new leadership.
- Long-term organic growth target: Management is sticking to the three-to-four-year outlook of 12% to 14% organic growth, assuming no macro or external changes.
- Growth composition: 50% of growth is expected from price increases and new product or new SKU introductions, with the remaining from volume growth.
- Therapeutic focus areas: Sharpening focus on growth drivers including orthopedics and women's health, with product launches in high-growth territory with better yield per patient expected somewhere at the end of H1 in the coming financial year.
- Sales mix flexibility: Management will bet on winning horses and the sales mix will change if that is where market need lies, but this will not change gross margins.
- Portfolio profile: The company is not into "very long" chronic therapy; the typical mix is roughly 35% to 40% acute with the remaining into semi-chronic.
Amrut Medhekar: "Yes, of course. So, we'll bet on the winning horses."
Yash Pharma Acquisition
- Integration performance: Since the acquisition two years ago, the Yash Pharma business has become among the fastest-growing within the portfolio and is now contributing more than expected lines towards growth.
- Margin alignment achieved: Margins which were about half of Jagsonpal Pharma at the time of acquisition have been aligned with overall corporate margins.
- Cash flow aligned: Cash flow generation from the acquired business is now fully aligned with the rest of the company.
- Depreciation impact: Depreciation moved up significantly since March 2024 due to the acquisition; assets are largely comprised of intangibles and trademarks being depreciated, while tangible assets are very small.
- Future expansion: Management is looking at further expansion of the Yash Pharma portfolio into the speciality mix.
Growth Outlook & Q4 Acceleration
- Q4 growth target: Management expects upward of 10% growth in the current quarter, not the lower end of double-digit, with benefits of the strategy refresh starting to reflect from Q4 itself.
- Short-term ambition: The COO is aiming for 50% more than industry growth in the short term.
- Sustainability beyond Q4: Management expects even better performance beyond Q4, with fiscal 2027 shaping up to be a very good year given the low base.
- RPM normalization expected: Historically, such phases of cyclicity in the RPM tend to rebound, and growth is expected to normalize and improve in the coming quarters.
- Industry volume context: Industry has been flattish other than new products and price growth; volume has been muted at very low single digits of 1% to 2% for three or four quarters.
- Field productivity focus: Focus remains on improving field productivity, strengthening brand investments where highest returns are seen, and driving more consistent execution across markets.
Amrut Medhekar: "Our idea, Sajal, at least what I am aiming in the short term is 50% more than the industry growth."
Capital Allocation
- M&A intent with discipline: M&A is a very strong intent but only disciplined, accretive deals are on the table; the market has not been supportive in terms of cost or price of acquisition.
- Both paths open: Both M&A and returning capital to shareholders are on the table; management will deploy capital in the most meaningful way that is EBITDA accretive, and is seriously looking at good acquisition candidates but assets remain very highly priced.
- Restructuring revenue impact: Per management, the revenue let go due to restructuring would be a small number around 1.5% to 2% of top line value, though this was an off-the-cuff estimate.
Manish Gupta: "M&A is a very strong intent at our end, but a disciplined M&A which is accretive for our shareholders and not dilutive. So that's very, very important for us. Market has not been supportive in terms of cost or price of acquisition."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Growth acceleration | Double-digit growth, upward of 10% | Q4 FY26 |
| Short-term growth vs industry | 50% more than industry growth | Short term (undated) |
| Long-term organic growth | 12% to 14% organic growth | Three to four years, assuming no macro or external changes |
| Product launches in high-growth territory | Better yield per patient | End of H1 in the coming financial year |
| Capital deployment | M&A (accretive) or return to shareholders; disciplined approach | Ongoing, subject to reasonable asset prices |
Key Metrics
| Metric | Q3 FY26 |
|---|---|
| Revenue | ₹73 cr, flattish |
| Revenue growth | -1%, impacted by internal recalibration and post-GST adjustment |
| EBITDA | ₹16.7 cr |
| EBITDA margin | 22.7% |
| PAT | ₹12.5 cr, +10% YoY |
| PAT margin | 17.1%, improved 180 bps YoY |
| 9M FY26 revenue | ₹223 cr, +6% YoY |
| 9M FY26 EBITDA | ₹50.3 cr, +5% YoY, margin at 22.6% |
| 9M FY26 PAT | ₹35.9 cr, +12.5% YoY, margin at 16.1% |
| Free cash balance | ₹176 cr, increased by ₹15.2 cr in the quarter |
| Stock cash generation | Over ₹15 cr during the quarter |
| IPM growth | ~8%, largely driven by price growth of 5% to 5.5%, volume growth muted |
| RPM growth | 3% to 3.5%, slower than IPM |
| One-time labour code impact | ₹2.1 cr, exceptional item |
| Revenue impact from SKU rationalization | ~1.5% to 2% of top line value |